Cargando…
A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada
We assessed physicians’ experiences of prescribing once-weekly (OW) semaglutide to patients with type 2 diabetes (T2D) in Canada. Physicians who had prescribed OW semaglutide to ≥2 patients with T2D in the past 12 months and had been doing so for ≥3 months were surveyed during 1–17 October 2018. Pre...
Autores principales: | Qureshy, Kamran, Ross Kirk, Andreas, Lyng Wolden, Michael, Abbas Mohseni Zonoozi, Amir, Liu, Aiden |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955057/ https://www.ncbi.nlm.nih.gov/pubmed/35350598 http://dx.doi.org/10.1097/XCE.0000000000000260 |
Ejemplares similares
-
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019) -
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021) -
Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials
por: Jendle, Johan, et al.
Publicado: (2019) -
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021) -
Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)